$GRTX strong GRTX looking strong for the past 3-4 days building a strong trend line we should be looking to break $5.10 above the cloud so that way we do have an uptrend confirmation we should look to pump up and make a nice zombie pump above $5.10
Next report date
Report period
Q1 2024
EPS estimate
−0.29USD
Revenue estimate
—
−1.4200USD
−59.08 MUSD
40.78 M
About Galera Therapeutics, Inc.
Sector
CEO
J. Mel Sorensen
Headquarters
Malvern
Website
Employees (FY)
7
Founded
2009
FIGI
BBG00M0WD1J3
Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. It is also involved in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis, and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
GRTX WEDGE!!!-Looking for the breakout here 15% SL
-looking to take an entry at 1-2 candlestick confirmations
-looking to short if we break down
GRTX important Price Target Upgrades Today !An "error" in previously released results sent Galera Therapeutics, Inc. (GRTX) stock price down by more than 70% in October.
Today GRTX was upgraded today by HC Wainwright to buy, 10usd price target and by BTIG Research to 15usd price target.
Have you bought it yesterday?
#GRTX New Target : USD 12.04 -13.07-17.05 @ 31%-60% -105%New Target : USD 12.04-13.07-17.05
Resistance 4 : USD 12.04
Resistance 3 : USD 10.83
Resistance 2 : USD 10.03
Resistance 1 : USD 09.33
Support 1 : USD 07.28
Support 2 : USD 05.88
Sector: Health Technology
Industry: Pharmaceuticals: Major
Galera Therapeutics, Inc. operates as a clinical-stage
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of GRTX is 0.2075 USD — it has increased by 13.57% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Galera Therapeutics, Inc. stocks are traded under the ticker GRTX.
Galera Therapeutics, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
GRTX stock is 19.32% volatile and has beta coefficient of −0.38. Check out the list of the most volatile stocks — is Galera Therapeutics, Inc. there?
GRTX earnings for the last quarter are −0.33 USD per share, whereas the estimation was −0.40 USD resulting in a 16.92% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about Galera Therapeutics, Inc. earnings.
Yes, you can track Galera Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
GRTX stock has fallen by 3.04% compared to the previous week, the month change is a 2.12% fall, over the last year Galera Therapeutics, Inc. has showed a 92.48% decrease.
GRTX net income for the last quarter is −5.59 M USD, while the quarter before that showed −15.07 M USD of net income which accounts for 62.93% change. Track more Galera Therapeutics, Inc. financial stats to get the full picture.
Today Galera Therapeutics, Inc. has the market capitalization of 11.29 M, it has increased by 12.24% over the last week.
No, GRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Galera Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 7.00 employees. See our rating of the largest employees — is Galera Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Galera Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Galera Therapeutics, Inc. stock shows the sell signal. See more of Galera Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.